Reduction of in-stent restenosis by cholesteryl ester transfer protein inhibition

Ben J. Wu*, Yue Li, Kwok L. Ong, Yidan Sun, Sudichhya Shrestha, Liming Hou, Douglas Johns, Philip J. Barter, Kerry Anne Rye

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

16 Citations (Scopus)


Objective - Angioplasty and stent implantation, the most common treatment for atherosclerotic lesions, have a significant failure rate because of restenosis. This study asks whether increasing plasma high-density lipoprotein (HDL) levels by inhibiting cholesteryl ester transfer protein activity with the anacetrapib analog, des-fluoro-anacetrapib, prevents stentinduced neointimal hyperplasia. Approach and Results - New Zealand White rabbits received normal chow or chow supplemented with 0.14% (wt/wt) desfluoro- anacetrapib for 6 weeks. Iliac artery endothelial denudation and bare metal steel stent deployment were performed after 2 weeks of des-fluoro-anacetrapib treatment. The animals were euthanized 4 weeks poststent deployment. Relative to control, dietary supplementation with des-fluoro-anacetrapib reduced plasma cholesteryl ester transfer protein activity and increased plasma apolipoprotein A-I and HDL cholesterol levels by 53±6.3% and 120±19%, respectively. Non-HDL cholesterol levels were unaffected. Des-fluoro-anacetrapib treatment reduced the intimal area of the stented arteries by 43±5.6% (P<0.001), the media area was unchanged, and the arterial lumen area increased by 12±2.4% (P<0.05). Desfluoro- anacetrapib treatment inhibited vascular smooth muscle cell proliferation by 41±4.5% (P<0.001). Incubation of isolated HDLs from des-fluoro-anacetrapib-treated animals with human aortic smooth muscle cells at apolipoprotein A-I concentrations comparable to their plasma levels inhibited cell proliferation and migration. These effects were dependent on scavenger receptor-B1, the adaptor protein PDZ domain-containing protein 1, and phosphatidylinositol-3-kinase/Akt activation. HDLs from des-fluoro-anacetrapib-treated animals also inhibited proinflammatory cytokine-induced human aortic smooth muscle cell proliferation and stent-induced vascular inflammation. Conclusions - Inhibiting cholesteryl ester transfer protein activity in New Zealand White rabbits with iliac artery balloon injury and stent deployment increases HDL levels, inhibits vascular smooth muscle cell proliferation, and reduces neointimal hyperplasia in an scavenger receptor-B1, PDZ domain-containing protein 1- and phosphatidylinositol-3-kinase/Akt-dependent manner.

Original languageEnglish
Pages (from-to)2333-2341
Number of pages9
JournalArteriosclerosis, Thrombosis, and Vascular Biology
Issue number12
Publication statusPublished - 1 Jan 2017
Externally publishedYes


  • Angioplasty
  • Apolipoprotein A-I
  • Cholesterol ester transfer protein
  • Iliac artery
  • Vascular smooth muscle cell proliferation


Dive into the research topics of 'Reduction of in-stent restenosis by cholesteryl ester transfer protein inhibition'. Together they form a unique fingerprint.

Cite this